MST1R and neoplasm: While the use of selective inhibitors and monoclonal antibodies against Ron have shown promise in vitro and in vivo inhibiting tumor growth, potential side effects and lack of complete inhibition [6, 8, 9] call for the development of new therapeutic approaches.